BNTX Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About BNTX Interactive Breakdown Better Bets vs. BNTX Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    BioNTech (BNTX)

    Market Price (8/27/2026): $111.4 | Market Cap: $-Sector: Health Care | Industry: Biotechnology

    BioNTech (BNTX)

    Market Price (8/27/2026): $111.4
    Market Cap: $-
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Megatrend and thematic drivers
    Megatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include mRNA Technology, Show more.

    Key risks
    BNTX key risks include [1] heavy dependence on sharply declining COVID-19 vaccine revenue, Show more.

    0 Megatrend and thematic drivers
    Megatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include mRNA Technology, Show more.
    1 Key risks
    BNTX key risks include [1] heavy dependence on sharply declining COVID-19 vaccine revenue, Show more.

    BNTX in ETFs

    Weight = BNTX's share of each fund

    IBB0.72%
    FNDF0.11%
    ONEQ0.03%

    Valuation & Metrics

    FYE: 12/31BNTX [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$2.6 Bil—
    FY 2026 Sales$1.9 Bil—
    FY 2027 Sales$1.9 Bil—
    FY 2026 Sales Growth-30.2%—
    FY 2027 Sales Growth0.5%13.0%
    EARNINGS
    LTM Net Income (GAAP) [3]$-1.7 Bil—
    FY 2026 Net Income (Non-GAAP)$-1.4 Bil—
    FY 2027 Net Income (Non-GAAP)$-1.1 Bil—
    FY 2027 Net Income Growth—19.1%
    FY 2026 EPS (Non-GAAP)$-5.73—
    FY 2027 EPS (Non-GAAP)$-5.66—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S—1.7
    FY 2027 P/S——
    FY 2026 P/E—7.9
    FY 2027 P/E——

    [1] BNTX forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 8/31/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    BNTXS&P 500
    REVENUE GROWTHVERY POOR
    Rev LTM ($ Bil)2.6
    Rev Chg Q-59.5%9.3%
    Rev Chg LTM-7.9%8.4%
    Rev Chg 3Y Avg-23.9%5.9%
    PROFITABILITYVERY POOR
    Op Inc LTM ($ Bil)-1.2
    CFO LTM ($ Bil)0.7
    Net Inc LTM ($ Bil)-1.7
    Op Mgn LTM-46.7%18.5%
    CFO/Rev LTM25.6%21.8%
    Net Inc Mgn-63.6%13.2%
    VALUATIONVERY HIGH
    P/S8.63.3
    P/CFO33.715.6
    P/FCF51.520.4
    P/E-13.623.5
    STABILITYVERY GOOD
    Debt/Equity0.010.19
    Cash/Assets0.730.06

    AI Analysis | Feedback

    MetricValueDateSource
    Number of ongoing pivotal clinical trials148042026Link
    Number of ongoing Phase 2 or 3 oncology trialsmore than 251122026Link
    Number of ongoing Phase 3 clinical trials (end of 2026 projection)151122026Link
    Number of novel-novel combination clinical trialsmore than 101132026Link
    Number of pivotal trials for pumitamig78042026Link
    Late-stage pipeline data readouts expected in 202671122026Link
    Late-stage and pivotal trial readouts through 2030 and beyond17+8042026Link

    Price Chart

    Recent
    8/04/2026Earnings ReleaseRev: $120 Mil (A) vs. $180 Mil (E)
    EPS: -3.70 (A) vs. $-2.40 (E)
    Upcoming
    11/03/2026Earnings ReleaseRev: $1.0 Bil (E)
    EPS: $0.86 (E)

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 8/26/2026

    BioNTech (BNTX) stock has gained about 10% since 4/30/2026 because of the following key factors:

    1. BioNTech's advanced oncology pipeline demonstrated significant progress and encouraging clinical data. The company achieved multiple milestones in 2026, including the initiation of six pivotal clinical trials, with five focusing on pumitamig and one on elfetabart drozuntecan. Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026 in May showed encouraging anti-tumor activity for pumitamig (BNT327/BMS986545) in the Phase 2 part of the ROSETTA Lung-02 trial for first-line non-small cell lung cancer (NSCLC). Additionally, positive results for trastuzumab pamirtecan in advanced HER2-expressing endometrial cancer were presented in June, and the company plans to file a biologics license application in 2026. This robust pipeline, encompassing 14 ongoing pivotal oncology trials, was highlighted as a key driver for investor focus, contributing to a stock jump of approximately 23% on August 19, 2026.

    2. The company initiated a substantial share repurchase program supported by a strong financial position. In May 2026, BioNTech authorized a share repurchase program of up to $1.0 billion, valid until May 6, 2027. During fiscal Q2 2026, which ended June 30, 2026, BioNTech repurchased 1,693,056 American Depositary Shares (ADSs) for a total consideration of $151.6 million (€131.8 million) at an average price of $89.50 (€77.85). This capital allocation strategy, aimed at enhancing shareholder value, was underpinned by the company's strong cash, cash equivalents, and security investments, which stood at €16.6 billion as of June 30, 2026.

    Show more
    Updated on 8/26/2026

    BioNTech (BNTX) stock has gained about 10% since 4/30/2026 because of the following key factors:

    1. BioNTech's advanced oncology pipeline demonstrated significant progress and encouraging clinical data. The company achieved multiple milestones in 2026, including the initiation of six pivotal clinical trials, with five focusing on pumitamig and one on elfetabart drozuntecan. Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026 in May showed encouraging anti-tumor activity for pumitamig (BNT327/BMS986545) in the Phase 2 part of the ROSETTA Lung-02 trial for first-line non-small cell lung cancer (NSCLC). Additionally, positive results for trastuzumab pamirtecan in advanced HER2-expressing endometrial cancer were presented in June, and the company plans to file a biologics license application in 2026. This robust pipeline, encompassing 14 ongoing pivotal oncology trials, was highlighted as a key driver for investor focus, contributing to a stock jump of approximately 23% on August 19, 2026.

    2. The company initiated a substantial share repurchase program supported by a strong financial position. In May 2026, BioNTech authorized a share repurchase program of up to $1.0 billion, valid until May 6, 2027. During fiscal Q2 2026, which ended June 30, 2026, BioNTech repurchased 1,693,056 American Depositary Shares (ADSs) for a total consideration of $151.6 million (€131.8 million) at an average price of $89.50 (€77.85). This capital allocation strategy, aimed at enhancing shareholder value, was underpinned by the company's strong cash, cash equivalents, and security investments, which stood at €16.6 billion as of June 30, 2026.

    3. European regulatory approval was secured for BioNTech's updated COVID-19 vaccine. In July 2026, the European Commission granted approval for BioNTech and Pfizer's XFG variant-adapted monovalent COVID-19 vaccine for the 2026-2027 vaccination season. This approval allows for continued participation in the seasonal COVID-19 vaccine market, providing an ongoing, albeit reduced, revenue stream for the company.

    4. A new Chief Executive Officer was appointed, signaling leadership continuity and strategic focus. On August 3, 2026, BioNTech announced the appointment of Guido Oelkers, Ph.D., to its Management Board as Chief Executive Officer, with his term commencing by February 1, 2027. Dr. Oelkers brings over 30 years of experience in the biotechnology and pharmaceutical industries, and his appointment is expected to support BioNTech's strategic transition into a multi-product biopharmaceutical company by 2030, with a strong focus on its expanding oncology pipeline.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The 8.8% change in BNTX stock from 4/30/2026 to 8/26/2026 was primarily driven by a 22.3% change in the company's P/S Multiple.
    (LTM values as of)43020268262026Change
    Stock Price ($)103.45112.568.8%
    Change Contribution By: 
    Total Revenues ($ Mil)2,8702,650-7.7%
    P/S Multiple8.810.822.3%
    Shares Outstanding (Mil)244253-3.6%
    Cumulative Contribution8.8%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    4/30/2026 to 8/26/2026
    ReturnCorrelation
    BNTX8.8% 
    Market (SPY)6.6%9.0%
    Sector (XLV)18.9%44.4%

    Fundamental Drivers

    The -1.0% change in BNTX stock from 1/31/2026 to 8/26/2026 was primarily driven by a -15.9% change in the company's Total Revenues ($ Mil).
    (LTM values as of)13120268262026Change
    Stock Price ($)113.75112.56-1.0%
    Change Contribution By: 
    Total Revenues ($ Mil)3,1522,650-15.9%
    P/S Multiple8.610.824.7%
    Shares Outstanding (Mil)239253-5.6%
    Cumulative Contribution-1.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    1/31/2026 to 8/26/2026
    ReturnCorrelation
    BNTX-1.0% 
    Market (SPY)11.0%19.7%
    Sector (XLV)12.6%35.5%

    Fundamental Drivers

    The 4.7% change in BNTX stock from 7/31/2025 to 8/26/2026 was primarily driven by a 14.4% change in the company's P/S Multiple.
    (LTM values as of)73120258262026Change
    Stock Price ($)107.50112.564.7%
    Change Contribution By: 
    Total Revenues ($ Mil)2,7462,650-3.5%
    P/S Multiple9.410.814.4%
    Shares Outstanding (Mil)240253-5.1%
    Cumulative Contribution4.7%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    7/31/2025 to 8/26/2026
    ReturnCorrelation
    BNTX4.7% 
    Market (SPY)22.2%24.4%
    Sector (XLV)34.8%37.2%

    Fundamental Drivers

    The 3.4% change in BNTX stock from 7/31/2023 to 8/26/2026 was primarily driven by a 397.6% change in the company's P/S Multiple.
    (LTM values as of)73120238262026Change
    Stock Price ($)108.87112.563.4%
    Change Contribution By: 
    Total Revenues ($ Mil)12,2132,650-78.3%
    P/S Multiple2.210.8397.6%
    Shares Outstanding (Mil)243253-4.2%
    Cumulative Contribution3.4%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    7/31/2023 to 8/26/2026
    ReturnCorrelation
    BNTX3.4% 
    Market (SPY)73.3%27.1%
    Sector (XLV)35.4%32.2%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    BNTX Return       
    Peers Return49%10%-23%-6%4%113%162%
    S&P 500 Return27%-19%24%23%16%12%104%

    Monthly Win Rates [3]
    BNTX Win Rate       
    Peers Win Rate57%53%30%48%53%68% 
    S&P 500 Win Rate75%42%67%75%67%50% 

    Max Drawdowns [4]
    BNTX Max Drawdown       
    Peers Max Drawdown-25%-26%-35%-35%-29%-19% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: MRNA, PFE, MRK, BMY, GILD.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 8/26/2026 (YTD)

    How Low Can It Go

    EventBNTXS&P 500
    2025 US Tariff Shock
      % Loss-27.5%-18.8%
      % Gain to Breakeven38.0%23.1%
      Time to Breakeven16 days79 days
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-14.9%-9.5%
      % Gain to Breakeven17.5%10.5%
      Time to Breakeven68 days24 days
    2020 COVID-19 Crash
      % Loss-11.5%-33.7%
      % Gain to Breakeven13.0%50.9%
      Time to Breakeven4 days140 days

    Compare to MRNA, PFE, MRK, BMY, GILD

    In The Past

    BioNTech's stock fell -27.5% during the 2025 US Tariff Shock. Such a loss loss requires a 38.0% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventBNTXS&P 500
    2025 US Tariff Shock
      % Loss-27.5%-18.8%
      % Gain to Breakeven38.0%23.1%
      Time to Breakeven16 days79 days

    Compare to MRNA, PFE, MRK, BMY, GILD

    In The Past

    BioNTech's stock fell -27.5% during the 2025 US Tariff Shock. Such a loss loss requires a 38.0% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About BioNTech (BNTX)

    BioNTech SE (BNTX) is a German biotechnology company specializing in the development and commercialization of advanced immunotherapies. Its core focus lies in leveraging cutting-edge scientific approaches, particularly mRNA technology, to create treatments for cancer and various infectious diseases. The company gained significant global recognition for its pivotal role in developing one of the first successful COVID-19 vaccines.

    The company boasts a deep and diverse pipeline of product candidates, primarily targeting different forms of cancer. This includes multiple experimental therapies such as personalized cancer vaccines (FixVac), neoantigen-specific immunotherapies, mRNA-based intratumoral therapies, RiboCytokines, and chimeric antigen receptor (CAR) T-cell immunotherapies. These investigational treatments are designed to address a wide range of solid tumors, including advanced melanoma, prostate cancer, HPV+ head and neck cancers, and pancreatic cancer. Beyond oncology, BioNTech is also actively developing prophylactic vaccines for other infectious diseases like influenza, as well as therapies for rare diseases.

    BioNTech's primary customers are global healthcare systems and patients afflicted with severe and life-threatening conditions, particularly various types of cancers and infectious diseases. To accelerate the development and global reach of its innovative therapies, BioNTech strategically collaborates with leading pharmaceutical and biotechnology companies such as Pfizer, Genentech, Sanofi, and Regeneron Pharmaceuticals, facilitating the extensive clinical trials and potential commercialization of its product candidates worldwide.

    AI Analysis | Feedback

    Here are 1-3 brief analogies to describe BioNTech (BNTX):

    • Like Moderna, but with a primary and extensive focus on pioneering mRNA-based immunotherapies for cancer, in addition to infectious disease vaccines.
    • The scientific engine behind Pfizer's successful COVID-19 vaccine, now deeply focused on developing a new generation of immunotherapies for cancer.

    AI Analysis | Feedback

    ```html
    • COVID-19 Vaccine: A highly effective prophylactic vaccine developed to prevent COVID-19 infection.
    • mRNA Cancer Immunotherapies: A diverse pipeline of mRNA-based therapies, including FixVac, neoantigen-specific, and intratumoral approaches, designed to treat various cancers.
    • RiboCytokines: Novel mRNA-encoded cytokine therapies aimed at treating solid tumors.
    • Chimeric Antigen Receptor T Cell (CAR T) Immunotherapies: Advanced cell therapies engineered to target and eliminate cancer cells.
    • Checkpoint Immunomodulators: Therapeutic agents that modify immune checkpoints to enhance the body's anti-cancer response.
    • Antibody & Small Molecule Oncology Therapeutics: A pipeline of traditional biologic (antibodies) and small molecule drugs targeting various cancers.
    • Prophylactic Vaccines (beyond COVID-19): Vaccines in development for other infectious diseases, such as influenza.
    • Rare Disease Protein Replacement Therapies: Therapies under development to replace missing or deficient proteins for rare genetic diseases.
    ```

    AI Analysis | Feedback

    BioNTech (BNTX) primarily sells its products and intellectual property through collaborations and partnerships with other pharmaceutical companies. These companies act as major customers or partners for the development, manufacturing, and commercialization of BioNTech's therapies and vaccines.

    Its major customer companies and collaborators include:

    • Genentech, Inc. (subsidiary of Roche Holding AG, RHHBY)
    • Sanofi S.A. (SNY)
    • Genmab A/S (GMAB)
    • Pfizer Inc. (PFE)
    • Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196.HK)
    • Regeneron Pharmaceuticals, Inc. (REGN)

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Here is the management team of BioNTech SE:

    Ugur Sahin, Chief Executive Officer

    Ugur Sahin is the co-founder and Chief Executive Officer of BioNTech. He is a physician, immunologist, and a leading expert in the development of novel approaches to combat cancer and infectious diseases, particularly in mRNA medicines. Dr. Sahin co-founded Ganymed Pharmaceuticals in 2001 with Özlem Türeci and Christoph Huber, focusing on anti-cancer drugs. Ganymed Pharmaceuticals was sold in 2016 for $1.4 billion. He co-founded BioNTech in 2008.

    Ramón Zapata, Chief Financial Officer

    Ramón Zapata is the Chief Financial Officer of BioNTech, a position he held as of May 2026.

    Özlem Türeci, Chief Medical Officer

    Özlem Türeci is the co-founder and Chief Medical Officer of BioNTech. She is a physician, immunologist, and cancer researcher with extensive translational and clinical experience. Dr. Türeci co-founded Ganymed Pharmaceuticals AG in 2001 with Ugur Sahin and Christoph Huber, where she served as CEO and Chief Medical Officer. Ganymed Pharmaceuticals was sold in 2016 for $1.4 billion. She co-founded BioNTech in 2008.

    Sierk Pötting, Chief Operating Officer

    Sierk Pötting joined BioNTech in 2014. He previously served as the Chief Financial Officer of BioNTech until July 2021, playing a fundamental role in the company's successful IPO in October 2019. He transitioned to the role of Chief Operating Officer to focus on manufacturing, digital transformation, and the expansion of BioNTech's global manufacturing footprint.

    James Ryan, Chief Legal and Chief Business Officer

    James Ryan serves as BioNTech's Chief Legal and Chief Business Officer. He took on the responsibilities of Chief Business Officer following Sean Marett's planned retirement.

    AI Analysis | Feedback

    BioNTech (BNTX) faces several key risks to its business:

    1. High Risk of Clinical Trial Failures and Regulatory Hurdles: A significant portion of BioNTech's pipeline consists of product candidates in early-stage clinical trials (Phase I and II), which inherently carry a high risk of failure. The company acknowledges that product candidates may not function as intended, could lead to undesirable side effects, experience clinical delays, or fail to achieve regulatory approval or market acceptance. For example, a partial clinical hold was placed on an early-stage trial for its antibody-drug conjugate BNT326/YL202 following patient deaths, and an individualized neoantigen therapy (BNT122) in colorectal cancer crossed a futility boundary in an interim analysis, with another urothelial cancer project being halted.
    2. Declining COVID-19 Vaccine Revenue and Diversification Challenges: BioNTech's revenue has been heavily dependent on its COVID-19 vaccine, with demand experiencing a sharp decline. This has resulted in substantial revenue plunges and net losses for the company, forcing it to scale back its mRNA production network. Future growth is contingent on the successful development and commercialization of new oncology assets, presenting a significant challenge to diversify revenue streams away from the rapidly diminishing COVID-19 vaccine sales.
    3. Intense Competition and Intellectual Property Challenges: The biotechnology and immunotherapy market is highly competitive. BioNTech faces intense competition in developing its product candidates and also notes challenges in protecting and enforcing its intellectual property rights. The success of competing therapies, such as a personalized melanoma vaccine from Moderna and Merck utilizing a similar mRNA cancer vaccine mechanism, highlights the competitive landscape, especially as BioNTech's equivalent programs are further behind in development.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    BioNTech SE (BNTX) operates in the biotechnology sector, focusing on immunotherapies for cancer and infectious diseases. The addressable markets for their main products and services are significant and span various oncology indications and prophylactic vaccines.

    Addressable Markets for BioNTech's Main Products and Services:

    • Advanced Melanoma: The global advanced melanoma market was valued at approximately USD 4.6 billion in 2025 across the seven major markets (US, EU4, UK, and Japan), and is projected to reach USD 11.9 billion by 2036. The global metastatic melanoma therapeutics market is estimated at USD 9.00 billion in 2026 and is expected to reach USD 20.53 billion by 2033.
    • Prostate Cancer: The global prostate cancer therapeutics market was valued at USD 12.6 billion in 2024 and is projected to reach USD 29.9 billion by 2034. Another estimate places the global market at USD 25.12 billion in 2025, projected to grow to USD 106.86 billion by 2034.
    • HPV+ Head and Neck Cancers (specifically HPV16-Positive Head and Neck Squamous Cell Carcinoma): The market for HPV16-Positive Head and Neck Squamous Cell Carcinoma (HNSCC) was valued at approximately USD 810 million in 2024 across the seven major markets (US, EU4, UK, Japan). The broader global head & neck cancer therapeutics market was calculated at USD 2.65 billion in 2025 and is projected to reach around USD 8.14 billion by 2035.
    • Triple-Negative Breast Cancer: The global triple-negative breast cancer treatment market was valued at USD 4.62 billion in 2025 and is predicted to reach USD 7.3 billion by 2035. Other estimates indicate the global triple-negative breast cancer (TNBC) treatment market size is expected to reach USD 1.4 billion in 2026 and USD 2.1 billion by 2033.
    • Ovarian Cancer: The global ovarian cancer drugs market size was valued at USD 3.4 billion in 2022 and is projected to grow to USD 5.7 billion by 2030. The global ovarian cancer market was valued at USD 5.86 billion in 2025 and is expected to reach USD 32.75 billion by 2033.
    • Non-Small Cell Lung Cancer (NSCLC): The global non-small cell lung cancer market was estimated at USD 20.2 billion in 2024 and is expected to grow to USD 53.9 billion by 2034. The global non-small cell lung cancer (NSCLC) therapeutics market size was valued at USD 38.49 billion in 2025, projected to grow to USD 66.04 billion by 2034.
    • Pancreatic Cancer: The global pancreatic cancer market size is expected to be worth around USD 11.5 billion by 2033, from USD 3.1 billion in 2023. The global pancreatic cancer treatment market size is expected to be valued at USD 4.3 billion in 2026 and projected to reach USD 12.6 billion by 2033.
    • COVID-19 Vaccine: The global COVID-19 vaccine market was valued at USD 8.23 billion in 2025 and is projected to grow to USD 15.35 billion by 2034. Another report indicates the global COVID-19 Vaccine Market size was worth around USD 14.25 billion in 2024 and is predicted to grow to around USD 42.66 billion by 2035. However, some projections indicate a contraction to USD 8.28 billion by 2030 from USD 13.71 billion in 2025.
    • Influenza Vaccine: The global influenza vaccine market size is calculated at USD 9.08 billion in 2025, projected to reach around USD 17.90 billion by 2035. Another source valued the global influenza vaccine market at USD 9.2 billion in 2025 and projected it to grow to USD 22.49 billion by 2034.

    AI Analysis | Feedback

    BioNTech (BNTX) is expected to drive future revenue growth over the next 2-3 years through a strategic shift towards its robust oncology pipeline, alongside continued advancements in its mRNA platform and strategic collaborations.

    1. Advancement and Commercialization of its Late-Stage Oncology Pipeline: BioNTech is heavily focused on transitioning into a multi-product oncology company, with potential product launches anticipated to begin in 2027-2028. The company's diversified late-stage oncology pipeline includes immunomodulators, antibody-drug conjugates (ADCs), and mRNA cancer immunotherapies. Key product candidates such as pumitamig (BNT327) and gotistobart are in pivotal clinical trials, with significant data readouts expected, positioning them as primary drivers of future revenue growth.

    2. Growth in Collaboration Revenue: Strategic partnerships, particularly with companies like Bristol Myers Squibb (BMS), are a significant source of expected revenue. For instance, BioNTech anticipates recognizing a substantial collaboration payment from Bristol Myers Squibb in the third quarter of 2026, associated with the advancement of their joint oncology programs.

    3. Development and Commercialization of Next-Generation mRNA-Based Vaccines and Therapies: While pivoting to oncology, BioNTech continues to develop its mRNA platform for infectious diseases beyond the initial COVID-19 vaccine. This includes the ongoing development and commercialization of variant-adapted COVID-19 vaccines for seasonal demand and the expansion of its mRNA technology to target other infectious diseases and rare diseases, representing a sustained, albeit re-prioritized, revenue stream.

    AI Analysis | Feedback

    Share Repurchases

    • BioNTech authorized a share repurchase program of up to $0.5 billion in March 2023, which commenced in June 2023 and concluded by November 2023.
    • A new share repurchase program was authorized in May 2026, allowing the company to buy back up to $1.0 billion in American Depositary Shares (ADSs) until May 6, 2027.
    • As of June 30, 2026, BioNTech had repurchased 1,693,056 ADSs for a total consideration of $151.6 million (€131.8 million) under the $1.0 billion program.

    Inbound Investments

    • BioNTech received $1.5 billion from its partnership with Bristol Myers Squibb as of November 3, 2025.
    • An additional €613 million payment from the Bristol Myers Squibb collaboration is anticipated to be recognized in the third quarter of 2026.

    Outbound Investments

    • In 2025, BioNTech acquired entities including BioNTech China (previously Biotheus) and CureVac.
    • BioNTech's co-founders are in the process of establishing an independent company focused on next-generation mRNA innovations, with planning ongoing in 2026.

    Capital Expenditures

    • Capital expenditures were €127.5 million in 2021, €329.2 million in 2022, and €249.4 million in 2023.
    • Projected capital expenditures are €286.5 million for 2024, €175.1 million for 2025, and €225.3 million for 2026.
    • The primary focus of capital expenditures is on research and development, scaling the business for late-stage development, commercial readiness in oncology, and manufacturing footprint consolidation.

    Peer Outperformance in Biotechnology

    null
    Share of Biotechnology constituents that BNTX has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    —
    insufficient peer history
    3Y
    —
    insufficient peer history
    5Y
    —
    insufficient peer history
    null
    Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is BNTX's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 7 14.0%87.3%117.8% CAH 414% · MCK 357% · COR 188%
    Health Care Services 20 22.7%46.1%3.7% HIMS 286% · RDNT 146% · DGX 81%
    Managed Health Care 8 34.9%-1.7%3.4% OSCR 122% · HQY 59% · ELV 16%
    Health Care Facilities 24 7.2%-3.6%-16.7% THC 266% · NHC 248% · ENSG 122%
    Health Care Equipment 51 -3.7%-5.2%-19.6% POCI 10775% · UFPT 342% · GKOS 218%
    Health Care Supplies 12 37.1%-12.4%-34.1% LNTH 292% · HAE 73% · MMSI 26%
    Pharmaceuticals 63 2.0%9.3%-37.2% LQDA 2543% · INDV 1254% · ETON 1135%
    Life Sciences Tools & Services 108 -1.7%-31.8%-71.9% SNWV 1888% · MEDP 243% · AXGN 207%
    Health Care Technology 21 -17.3%-55.8%-75.0% SPOK 120% · HSTM -1% · VEEV -26%
    Biotechnology ← 366 11.3%-23.7%-78.2% BRTX 108350% · DNTH 1672% · CELZ 1600%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Latest Trefis Analyses

    TitleDate
    0DASHBOARDS 
    1BioNTech SE (BNTX) Stock Has 60% Chance Of Rise In The Next One Month02/13/2023
    2[10/21/2022] BioNTech SE (BNTX) Shares Moved 11% Today  (4% likelihood event)10/21/2022
    3Dates Cached For BNTX10/21/2022
    4BioNTech SE (BNTX) Stock Has 63% Chance Of Rise In The Next One Month09/23/2022
    5BioNTech: Highest And Lowest Correlated Assets 04/17/2022
    6BioNTech To S&P 500 Ratio04/07/2022
    7BioNTech Trading Activity04/07/2022
    8BioNTech Market Momentum03/29/2022
    9BioNTech Excess Market Return vs S&P 50003/25/2022
    10ARTICLES 
    11What’s Happening With BioNTech Stock?01/19/2022
    12Down 34% Last Month, Should You Buy BioNTech Stock For Near-Term Gains?10/18/2021
    13What’s New With BioNTech Stock?09/28/2021
    14What Drove BioNTech Stock’s Incredible Rise From $80 To $420 This Year?08/11/2021
    15Why BioNTech Stock’s Rally Isn’t Done Yet06/11/2021

    Recent Active Movers

    Top Gainers

    TickerCompanyCategory1W RtnYTD Rtn
    ETHAiShares Ethereum Trust ETFCryptocurrency17.4%-16.9%
    IBITiShares Bitcoin Trust ETFCryptocurrency14.6%-10.5%
    FBTCFidelity Wise Origin Bitcoin FundCryptocurrency14.6%-10.4%
    URAGlobal X Uranium ETFEquity6.8%12.5%
    RINGiShares MSCI Global Gold Miners ETFEquity6.2%22.7%
    EWZiShares MSCI Brazil ETFEquity4.3%12.4%
    ILFiShares Latin America 40 ETFEquity4.0%15.0%
    UNGUnited States Natural Gas Fund LPCommodity4.0%-15.1%
    IYMiShares U.S. Basic Materials ETFEquity3.2%27.7%
    ARKKARK Innovation ETFEquity3.0%11.5%

    Top Losers

    TickerCompanyCategory1W RtnYTD Rtn
    NASATema Space Innovators ETFEquity-5.4%-6.1%
    MISLFirst Trust Indxx Aerospace & Defense...Equity-4.1%4.9%
    ITAiShares U.S. Aerospace & Defense ETFEquity-4.0%10.2%
    ARKXARK Space & Defense Innovation ETFEquity-3.5%-7.0%
    KWEBKraneShares CSI China Internet ETFEquity-3.5%-22.8%
    ARKQARK Autonomous Technology & Robotics ETFEquity-2.9%6.7%
    USOUnited States Oil Fund LPCommodity-2.7%84.1%
    BOTZGlobal X Funds Global X Robotics & Ar...Equity-2.1%-1.7%
    XLEState Street Energy Select Sector SPD...Equity-1.8%40.5%
    IWOiShares Russell 2000 Growth ETFEquity-1.3%19.3%

    Top Gainers

    TickerCompanyCategory1M RtnYTD Rtn
    RINGiShares MSCI Global Gold Miners ETFEquity41.6%22.7%
    ETHAiShares Ethereum Trust ETFCryptocurrency28.7%-16.9%
    URAGlobal X Uranium ETFEquity23.4%12.5%
    IBITiShares Bitcoin Trust ETFCryptocurrency23.0%-10.5%
    FBTCFidelity Wise Origin Bitcoin FundCryptocurrency23.0%-10.4%
    SLViShares Silver TrustCommodity19.1%-4.4%
    ARKKARK Innovation ETFEquity18.4%11.5%
    EWYiShares MSCI South Korea ETFEquity18.3%84.3%
    GDEWisdomTree Efficient Gold Plus Equity...Equity16.2%-0.2%
    PPLTETFS Physical Platinum SharesCommodity14.2%-10.9%

    Top Losers

    TickerCompanyCategory1M RtnYTD Rtn
    XLUState Street Utilities Select Sector ...Equity-4.4%2.6%
    KWEBKraneShares CSI China Internet ETFEquity-3.8%-22.8%
    ITAiShares U.S. Aerospace & Defense ETFEquity-3.5%10.2%
    USRTiShares Core U.S. REIT ETFReal Estate-3.4%18.4%
    SCHHSchwab U.S. REIT ETFReal Estate-3.0%15.9%
    KREState Street SPDR S&P Regional Bankin...Equity-2.9%15.7%
    REETiShares Global REIT ETFReal Estate-2.8%13.1%
    IYRiShares U.S. Real Estate ETFReal Estate-2.3%11.9%
    VNQVanguard Real Estate ETFReal Estate-2.3%13.6%
    XLREState Street Real Estate Select Secto...Real Estate-2.0%12.5%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    BNTXMRNAPFEMRKBMYGILDMedian
    NameBioNTech Moderna Pfizer Merck Bristol-.Gilead S. 
    Mkt Price-149.6628.30153.1067.57148.09148.09
    Mkt Cap-59.6161.3378.2138.0184.1161.3
    Rev LTM-2,21063,69566,56949,18730,45649,187
    Op Inc LTM--3,32017,0196,98513,84211,71611,716
    FCF LTM--1,24410,98516,06311,44012,94311,440
    FCF 3Y Avg--2,9089,41114,64412,9889,7369,736
    CFO LTM--1,07313,40119,96712,78213,55213,401
    CFO 3Y Avg--2,33712,19818,39714,28210,29612,198

    Growth & Margins

    BNTXMRNAPFEMRKBMYGILDMedian
    NameBioNTech Moderna Pfizer Merck Bristol-.Gilead S. 
    Rev Chg LTM--27.7%-0.2%4.6%3.1%5.5%3.1%
    Rev Chg 3Y Avg--39.7%-5.2%4.5%2.9%3.6%2.9%
    Rev Chg Q-4.4%2.6%5.1%5.7%10.2%5.1%
    QoQ Delta Rev Chg LTM-0.3%0.6%1.2%1.5%2.4%1.2%
    Op Inc Chg LTM--1.4%2.1%-64.8%39.1%7.6%2.1%
    Op Inc Chg 3Y Avg--325.2%233.9%36.7%22.3%-0.8%22.3%
    Op Mgn LTM--150.2%26.7%10.5%28.1%38.5%26.7%
    Op Mgn 3Y Avg--116.8%18.7%22.4%21.4%37.0%21.4%
    QoQ Delta Op Mgn LTM-4.6%-0.5%-9.2%0.1%-1.6%-0.5%
    CFO/Rev LTM--48.6%21.0%30.0%26.0%44.5%26.0%
    CFO/Rev 3Y Avg--67.3%19.7%28.6%29.9%35.2%28.6%
    FCF/Rev LTM--56.3%17.2%24.1%23.3%42.5%23.3%
    FCF/Rev 3Y Avg--83.5%15.1%22.8%27.2%33.3%22.8%

    Valuation

    BNTXMRNAPFEMRKBMYGILDMedian
    NameBioNTech Moderna Pfizer Merck Bristol-.Gilead S. 
    Mkt Cap-59.6161.3378.2138.0184.1161.3
    P/S-27.02.55.72.86.05.7
    P/Op Inc--17.99.554.110.015.710.0
    P/EBIT--19.623.449.210.1-192.310.1
    P/E--18.937.2119.214.9-56.814.9
    P/CFO--55.512.018.910.813.612.0
    Total Yield--5.3%8.8%3.0%10.4%0.4%3.0%
    Dividend Yield-0.0%6.1%2.2%3.7%2.2%2.2%
    FCF Yield 3Y Avg--15.3%6.7%5.6%13.5%7.7%6.7%
    D/E-0.00.40.10.30.10.1
    Net D/E--0.10.30.10.20.10.1

    Returns

    BNTXMRNAPFEMRKBMYGILDMedian
    NameBioNTech Moderna Pfizer Merck Bristol-.Gilead S. 
    1M Rtn-169.0%14.7%17.1%8.0%13.5%14.7%
    3M Rtn-214.3%9.9%28.2%18.8%11.5%18.8%
    6M Rtn-191.3%8.0%26.9%12.6%1.9%12.6%
    12M Rtn-505.2%21.5%86.2%50.0%32.4%50.0%
    3Y Rtn-33.7%-5.7%52.4%25.3%112.7%33.7%
    1M Excs Rtn-164.9%8.8%12.8%2.9%6.9%8.8%
    3M Excs Rtn-212.3%7.8%26.2%16.7%9.4%16.7%
    6M Excs Rtn-180.8%-2.5%16.3%2.1%-8.6%2.1%
    12M Excs Rtn-471.2%1.3%66.3%31.0%13.9%31.0%
    3Y Excs Rtn--39.7%-81.7%-21.3%-48.8%40.8%-39.7%

    Comparison Analyses

    null

    FDA Approved Drugs Data

    Expand for More
    FDA-Licensed Biologics (CBER · Purple Book)
    Post-Approval Fwd Returns
    FDA
    BLA #    		Brand
    Name    		Generic
    Name    		License
    Type    		First
    Approval    		Latest
    Approval    		3M
    Rtn    		6M
    Rtn    		1Y
    Rtn    		2Y
    Rtn    		Total
    Rtn
    125742  Comirnatycovid-19 vaccine, mrna351(a)8/23/20218/27/2025-15.8%-58.9%-61.0%-67.4%-70.2%
     Collapse to Preview
    FDA-Licensed Biologics (CBER · Purple Book)
    Post-Approval Fwd Returns
    FDA
    BLA #    		Brand
    Name    		Generic
    Name    		License
    Type    		First
    Approval    		Latest
    Approval    		3M
    Rtn    		6M
    Rtn    		1Y
    Rtn    		2Y
    Rtn    		Total
    Rtn
    125742  Comirnatycovid-19 vaccine, mrna351(a)8/23/20218/27/2025-15.8%-58.9%-61.0%-67.4%-70.2%

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/2023
    Filing Date8/4/20265/5/20263/10/202611/12/20258/4/20255/5/20253/10/202511/4/20248/5/20245/6/20243/20/202411/6/2023
    Key Financials Quarterly            
    Total Revenue1061189071,5192611831,1901,2451291881,479895
    Ebitda-589-443-512778-348-399317426-752-289745271
    Operating Income-939-671-280654-472-562103381-694-50771173
    Net Income-821-532-305-29-387-416260198-808-315458161
    EPS-3.24-2.10-1.25-0.12-1.60-1.731.080.82-3.36-1.311.910.67
    Key Financials TTM            
    Total Revenue TTM2,6502,8052,8703,1522,8782,7462,7513,0402,6912,7303,8196,618
    Ebitda TTM-765-524-480349-4-408-298129-263481,4053,864
    Operating Income TTM-1,236-770-660-276-549-770-716-108-416-2868763,627
    Net Income TTM-1,686-1,252-1,136-572-345-766-665-467-5041139302,751
    Growth Rates Quarterly            
    Total Revenue Growth-59.5%-35.4%-23.7%22.0%102.6%-2.6%-19.5%39.0%-23.3%-85.3%-65.4%-74.1%
    EBITDA Growth-69.3%-11.0%-261.2%82.9%53.8%-38.1%-57.4%57.2%-98.5%-137.6%-76.7%-89.1%
    Operating Income Growth-98.9%-19.5%-371.3%71.6%31.9%-10.7%-85.5%421.3%-23.1%-177.5%-79.5%-96.7%
    Net Income Growth-112.3%-27.9%-217.5%-114.5%52.1%-32.0%-43.3%23.3%-324.3%-162.7%-79.9%-91.0%
    Margins Quarterly            
    EBITDA Margin-557.9%-374.9%-56.4%51.2%-133.4%-218.2%26.7%34.2%-584.7%-153.9%50.4%30.2%
    Operating Income Margin-888.9%-568.3%-30.9%43.1%-181.0%-307.2%8.7%30.6%-538.9%-270.4%48.1%8.2%
    Net Income Margin-777.3%-450.4%-33.6%-1.9%-148.2%-227.5%21.8%15.9%-627.7%-168.0%31.0%17.9%
    Cash & Debt            
    Total Cash14,77914,63914,87714,51914,03714,11016,78416,70917,29615,66616,54915,749
    Total Debt316303267245270293254244255236219202
    Net Debt / (Cash)-14,463-14,336-14,610-14,273-13,767-13,817-16,529-16,466-17,041-15,430-16,330-15,547
    Cash Flows Quarterly            
    FCF from Operations10-421310781146-781-463-6391,627-317851811
    Cash Flows TTM            
    FCF from Operations TTM680816456-317-1,736-2562081,5222,9725,7325,3715,350
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases129-0-0-0-0-0-0-0-0-01302
    Return on Invested Capital (ROIC) Quarterly            
    ROIC------------
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM------------

    Segment Financials

    Revenue by Segment
    $ Mil20222018
    Single Segment17,311 
    Business Service 0
    Clinical 37
    Manufacturing 26
    Product Sales & External Services 19
    Technology Platform 46
    Total17,311128


    Operating Income by Segment
    $ Mil2018
    Product Sales & External Services2
    Adjustments0
    Clinical-8
    Manufacturing-8
    Technology Platform-14
    Business Service-25
    Total-54


    Price Behavior

    Price Behavior
    Market Price$112.56 
    Market Cap ($ Bil)28.5 
    First Trading Date10/10/2019 
    Distance from 52W High-5.7% 
       50 Days200 Days
    DMA Price$94.58$97.70
    DMA Trenddownup
    Distance from DMA19.0%15.2%
     3M1YR
    Volatility53.2%47.1%
    Downside Capture10.9685.58
    Upside Capture99.5175.85
    Correlation (SPY)9.2%23.9%
    BNTX Betas & Captures as of 7/31/2026

     1M2M3M6M1Y3Y
    Beta-0.450.120.190.670.870.82
    Up Beta-0.891.541.391.251.340.99
    Down Beta0.680.410.440.810.910.61
    Up Capture-85%-56%-47%10%40%39%
    Bmk +ve Days11223567138427
    Stock +ve Days11203060125354
    Down Capture-52%-25%3%82%94%98%
    Bmk -ve Days11212859114326
    Stock -ve Days11233365125395

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with BNTX
    BNTX7.2%47.0%0.29-
    Sector ETF (XLV)29.2%15.9%1.4136.8%
    Equity (SPY)20.3%12.8%1.1823.8%
    Gold (GLD)36.2%28.8%1.0621.0%
    Commodities (DBC)37.6%20.3%1.46-0.2%
    Real Estate (VNQ)11.8%13.6%0.5724.0%
    Bitcoin (BTCUSD)-28.6%43.6%-0.6524.4%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with BNTX
    BNTX-21.0%53.5%-0.24-
    Sector ETF (XLV)6.8%15.1%0.2733.7%
    Equity (SPY)13.2%17.2%0.5929.8%
    Gold (GLD)20.3%18.7%0.898.1%
    Commodities (DBC)10.4%19.6%0.41-2.0%
    Real Estate (VNQ)2.5%18.9%0.0323.8%
    Bitcoin (BTCUSD)12.0%52.7%0.4119.7%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with BNTX
    BNTX22.9%75.7%0.72-
    Sector ETF (XLV)10.7%16.7%0.5226.9%
    Equity (SPY)15.2%17.9%0.7222.5%
    Gold (GLD)12.6%16.3%0.646.8%
    Commodities (DBC)7.4%18.0%0.33-1.7%
    Real Estate (VNQ)5.1%20.7%0.2114.9%
    Bitcoin (BTCUSD)63.5%66.1%1.0310.0%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date8142026
    Short Interest: Shares Quantity2.5 Mil
    Short Interest: % Change Since 73120261.7%
    Average Daily Volume1.1 Mil
    Days-to-Cover Short Interest2.3 days
    Basic Shares Quantity253.3 Mil
    Short % of Basic Shares1.0%

    Returns Analyses

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/04/20266-K
    03/31/202605/05/20266-K
    12/31/202503/10/202620-F
    06/30/202508/04/20256-K
    03/31/202505/05/20256-K
    12/31/202403/10/202520-F
    09/30/202411/04/20246-K
    06/30/202408/05/20246-K
    03/31/202405/06/20246-K
    12/31/202303/20/202420-F
    09/30/202311/06/20236-K
    06/30/202308/07/20236-K
    03/31/202305/08/20236-K
    12/31/202203/27/202320-F
    09/30/202211/07/20226-K
    06/30/202208/08/20226-K
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/04/20266-K
    03/31/202605/05/20266-K
    12/31/202503/10/202620-F
    06/30/202508/04/20256-K
    03/31/202505/05/20256-K
    12/31/202403/10/202520-F
    09/30/202411/04/20246-K
    06/30/202408/05/20246-K
    03/31/202405/06/20246-K
    12/31/202303/20/202420-F
    09/30/202311/06/20236-K
    06/30/202308/07/20236-K
    03/31/202305/08/20236-K
    12/31/202203/27/202320-F
    09/30/202211/07/20226-K
    06/30/202208/08/20226-K
    03/31/202205/09/20226-K
    12/31/202103/30/202220-F
    09/30/202111/09/20216-K
    06/30/202108/09/20216-K
    03/31/202105/10/20216-K
    12/31/202003/30/202120-F
    09/30/202011/12/20206-K
    06/30/202008/11/20206-K
    03/31/202005/12/20206-K
    12/31/201903/31/202020-F
    09/30/201911/14/20196-K
    06/30/201910/11/2019424B4

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 8/26/2026